[Immunosuppression in kidney transplantation]

Prog Urol. 2011 Apr;21(4):250-3. doi: 10.1016/j.purol.2010.08.048. Epub 2010 Oct 20.
[Article in French]

Abstract

These last years, major progress in renal transplantation were observed, especially in immunosuppression with new drugs available. In the first part of this paper, immunological process of allogenic response is described. Then, the different classes of immunosuppressive drugs, their potential associations and new trends in immunosuppression are presented.

Publication types

  • Review

MeSH terms

  • Abatacept
  • Anti-Inflammatory Agents / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antilymphocyte Serum / therapeutic use
  • Basiliximab
  • Calcineurin Inhibitors
  • Daclizumab
  • Humans
  • IMP Dehydrogenase / antagonists & inhibitors
  • Immunoconjugates / therapeutic use
  • Immunoglobulin G / therapeutic use
  • Immunosuppression Therapy*
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Transplantation*
  • Recombinant Fusion Proteins / therapeutic use
  • TOR Serine-Threonine Kinases / antagonists & inhibitors

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antilymphocyte Serum
  • Calcineurin Inhibitors
  • Immunoconjugates
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Recombinant Fusion Proteins
  • Abatacept
  • Basiliximab
  • Daclizumab
  • IMP Dehydrogenase
  • MTOR protein, human
  • TOR Serine-Threonine Kinases